Abstract
Immunotherapy has potential as a disease-modifying approach to the treatment of Alzheimer's disease. In this study, Santuccione et al. found that among individuals with Alzheimer's disease, those who exhibit slower cognitive decline have higher blood levels of antibodies specific for the neuronal cytoskeletal protein ankyrin G (ANKG; also known as ANK3). ArcAβ mice (a transgenic mouse model of Alzheimer's disease) that were vaccinated with ANKG had fewer and smaller amyloid plaques than unvaccinated animals, as well as less spine loss. Thus, taking advantage of the adaptive immune response to ANKG could be a potential approach for Alzheimer's disease immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
